Rapid Healing of Cutaneous Leishmaniasis by High-Frequency Electrocauterization and Hydrogel Wound Care with or without DAC N-055: A Randomized Controlled Phase IIa Trial in Kabul

PLoS Neglected Tropical Diseases

Volumn 8, Issue 2, 2014, Pages

  Jebran, Ahmad Fawad ^a,d   Schleicher, Ulrike ^a   Steiner, Reto ^b,e   Wentker, Pia ^a   Mahfuz, Farouq ^b,f   Stahl, Hans Christian ^c   Amin, Faquir Mohammad ^b   Bogdan, Christian ^a   Stahl, Kurt Wilhelm ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Leishmania Clinic German Medical Service (NGO)   (Afghanistan)

^c Waisenmedizin eV Promoting Access to Care with Essential Medicine Non Profit Organization   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e Christusträger Communität ^*  (Switzerland)

^f German Medical Diagnostic Center Kabul DK GMDC Ltd   (Afghanistan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; POLYACRYLIC ACID; SODIUM CHLORITE;

ADOLESCENT; ADULT; AGED; AMASTIGOTE; ARTICLE; CAUTERIZATION; CHILD; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE BLIND PROCEDURE; EPITHELIZATION; FEMALE; HUMAN; HUMAN TISSUE; HYDROGEL; IMMUNOHISTOLOGY; KELOID; LEISHMANIA TROPICA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE LOAD; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN BIOPSY; SKIN LEISHMANIASIS; SUPERINFECTION; TREATMENT RESPONSE; WOUND CLOSURE; WOUND HEALING;

ADOLESCENT; ADULT; AFGHANISTAN; AGED; CHILD; CHILD, PRESCHOOL; CHLORIDES; ELECTROCOAGULATION; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PARASITE LOAD; WOUND HEALING; YOUNG ADULT;

EID: 84895751024     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002694     Document Type: Article

References (88)

1. Bailey MS, Lockwood DN, (2007) Cutaneous leishmaniasis. Clin Dermatol 25: 203-211.
2. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
3. WHO (2010) Control of Leishmaniasis. WHO Technical Report Series 949: 1-187.
4. Bogdan C, (2012) Leishmaniasis in Rheumatology, Hematology, and Oncology: Epidemiological, Immunological, and Clinical Aspects and Caveats. Ann Rheumatic Diseases 71 (suppl. 2) (): i60-i66.
5. Kibbi AG, Karam PG, Kurban AK, (1987) Sporotrichoid leishmaniasis in patients from Saudi Arabia: clinical and histologic features. J Am Acad Dermatol 17: 759-764.
6. Gaafar A, Fadl A, el Kadaro AY, el Hassan MM, Kemp M, et al. (1994) Sporotrichoid cutaneous leishmaniasis due to Leishmania major of different zymodemes in the Sudan and Saudi Arabia: a comparative study. Trans R Soc Trop Med Hyg 88: 552-554.
7. Doudi M, Setorki M, Narimani M, (2012) Bacterial superinfection in zoonotic cutaneous leishmaniasis. Med Sci Monit 18: BR356-361.
8. Kassi M, Kassi M, Afghan AK, Rehman R, Kasi PM, (2008) Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in Pakistan and Afghanistan. PLoS Negl Trop Dis 2: e259.
9. Sakthianandeswaren A, Elso CM, Simpson K, Curtis JM, Kumar B, et al. (2005) The wound repair response controls outcome to cutaneous leishmaniasis. Proc Natl Acad Sci U S A 102: 15551-15556.
10. Tasew G, Nylen S, Lieke T, Lemu B, Meless H, et al. (2010) Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration. PLoS Negl Trop Dis 4: e844.
11. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
12. Reithinger R, Mohsen M, Aadil K, Sidiqi M, Erasmus P, et al. (2003) Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan. Emerg Infect Dis 9: 727-729.
13. Killick-Kendrick R, Killick-Kendrick M, Tang Y, (1995) Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: the high susceptibility of Phlebotomus sergenti to Leishmania tropica. Trans R Soc Trop Med Hyg 89: 477.
14. Hewitt S, Reyburn H, Ashford R, Rowland M, (1998) Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Trans R Soc Trop Med Hyg 92: 273-274.
15. Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, et al. (2005) Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40: 1148-1155.
16. Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, et al. (2008) Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 19: 394-396.
17. van Thiel PP, Leenstra T, Kager PA, de Vries HJ, van Vugt M, et al. (2010) Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 50: 80-83.
18. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, et al. (2013) Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 7: e2130.
19. Gonzalez U, Pinart M, Reveiz L, Alvar J, (2008) Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev pp. CD005067.
20. Svensson T, Nelander B, Bernhardsson A, Karlström G, (1999) Infrared spectroscopic and ab initio study of HOOClO2. J Phys Chem 103: 4432-4437.
21. Hollemann-Wiberg (2007) Lehrbuch der Anorganischen Chemie. BerlinBoston and Peking: Walter de Gruyter GmbH. 485 p.
22. Stahl KW, Wannowius KJ (1999) Peroxochloric acid, derivatives, and anions, salts thereof, method for producing them and use of the same. German Priorities 199 07 256.6 19th February 1999 and 199 50 632.9 20th October 1999. http://patentscopewipoint/search/en/WO2000048940.
23. Radi R, Denicola A, Freeman BA, (1999) Peroxynitrite reactions with carbon dioxide-bicarbonate. Methods Enzymol 301: 353-367.
24. Witke K, Steiger T, Jancke H, Beining K, Polak W, (2002) Investigations of structure and stability of the tetrachlorinedecaoxide anion complex (TCDO). Z Anorg Allg Chem 628: 7070-7710.
25. Kühne FW, (1983) Stabilized activated oxygen and pharmaceutical compositions containing it. Chem Abstracts 90: 218605.
26. Youngman RJ, Wagner GR, Kuhne FW, Elstner EF, (1986) Time kinetics of hemoglobin and myoglobin activation by tetrachlorodecaoxide (TCDO). Free Radic Res Commun 1: 311-319.
27. Umile TP, Groves JT, (2011) Catalytic generation of chlorine dioxide from chlorite using a water-soluble manganese porphyrin. Angew Chem Int Ed Engl 50: 695-698.
28. Hicks SD, Petersen JL, Bougher CJ, Abu-Omar MM, (2011) Chlorite dismutation to chlorine dioxide catalyzed by a water-soluble manganese porphyrin. Angew Chem Int Ed Engl 50: 699-702.
29. Akin EW, Hoff JC, Lippy EC, (1982) Waterborne outbreak control: which disinfectant? Environ Health Perspect 46: 7-12.
30. Klebanoff SJ, (2005) Myeloperoxidase: friend and foe. J Leukoc Biol 77: 598-625.
31. Gillissen G, Kuhne FW, Breuer-Werle M, Melzer B, Ostendorp H, (1986) Increased resistance towards two systemic experimental infections by tetrachlorodecaoxygen anion complex. Possible implications of cellular and humoral immunity. Arzneimittelforschung 36: 1778-1782.
32. Ennen J, Werner K, Kuhne FW, Kurth R, (1993) Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen. AIDS 7: 1205-1212.
33. Stoll P, Huber H, Pelz K, Weingart D, (1993) Antimicrobial effects of the tetrachlorodecaoxygen-anion complex on oropharyngeal bacterial flora: an in vitro study. Chemotherapy 39: 40-47.
34. Raffanti SP, Schaffner W, Federspiel CF, Blackwell RB, Ching OA, et al. (1998) Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection 26: 202-207.
35. Hinz J, Hautzinger H, Stahl KW, (1986) Rationale for and results from a randomised, double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. The Lancet 327 (issue 8485) (): 825-828.
36. Ivankovic S, Kempf SR, (1988) Regenerative effects of tetrachlorodecaoxide in BD IX rats after total-body gamma irradiation. Radiat Res 115: 115-123.
37. Malik IA, Moid I, Haq S, Sabih M, (1997) A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis. J Pain Symptom Manage 14: 82-87.
38. Veerasarn V, Boonnuch W, Kakanaporn C, (2006) A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis. Gynecol Oncol 100: 179-184.
39. Yingsakmongkol N, Maraprygsavan P, Sukosit P, (2011) Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial. J Foot Ankle Surg 50: 635-640.
40. Tissot M, Roch-Arveiller M, Mathieu J, Giroud JP, Stahl KW, (1990) Anti-inflammatory properties of a novel wound healing and immunomodulating agent, tetrachlorodecaoxygen complex (TCDO). Agents Actions 31: 368-374.
41. Kempf SR, Blaszkiewitz K, Reim M, Ivankovic S, (1993) Comparative study on the effects of chlorite oxygen reaction product TCDO (tetrachlorodecaoxygen) and sodium chlorite solution (NaClO2) with equimolar chlorite content on bone marrow and peripheral blood of BDIX rats. Drugs Exp Clin Res 19: 165-174.
42. McGrath MS, Kahn JO, Herndier BG, (2002) Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs 3: 365-373.
43. Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, et al. (2004) Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol 229: 149-158.
44. Kuhne L, Konstandin M, Samstag Y, Meuer S, Giese T, et al. (2011) WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells. J Biomed Biotechnol 2011: 436587.
45. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL, (2007) Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis 6: 3.
46. Al-Hucheimi SN, Sultan BA, Al-Dhalimi MA, (2009) A comparative study of the diagnosis of Old World cutaneous leishmaniasis in Iraq by polymerase chain reaction and microbiologic and histopathologic methods. Int J Dermatol 48: 404-408.
47. Stenger S, Donhauser N, Thüring H, Röllinghoff M, Bogdan C, (1996) Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med 183: 1501-1514.
48. Marfurt J, Niederwieser I, Makia ND, Beck HP, Felger I, (2003) Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 46: 115-124.
49. Murray HW, Cartelli DM, (1983) Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and-independent leishmanicidal activity. J Clin Invest 72: 32-44.
50. Douvas GS, Looker DL, Vatter AE, Crowle AJ, (1985) Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 50: 1-8.
51. Gilje O, (1948) On taping (adhesive tape treatment) of leg ulcers. Acta Derm Venereol 28: 454-467.
52. Bloom H, (1945) "Cellophane" dressing for second-degree burns. The Lancet 246 (issue 6375) (): 559.
53. Schilling RS, Roberts M, Goodman N, (1950) Clinical trial of occlusive plastic dressings. Lancet 1: 293-296.
54. Beattie AD, Dodd H, Nixon WC, (1951) A post-operative window dressing. Br Med J 1: 816-817.
55. Chaby G, Senet P, Vaneau M, Martel P, Guillaume JC, et al. (2007) Dressings for acute and chronic wounds: a systematic review. Arch Dermatol 143: 1297-1304.
56. Powers JG, Morton LM, Phillips TJ, (2013) Dressings for chronic wounds. Dermatol Ther 26: 197-206.
57. Kordestani S, Shahrezaee M, Tahmasebi MN, Hajimahmodi H, Haji Ghasemali D, et al. (2008) A randomised controlled trial on the effectiveness of an advanced wound dressing used in Iran. J Wound Care 17: 323-327.
58. Edwards J, Stapley S, (2010) Debridement of diabetic foot ulcers. Cochrane Database Syst Rev pp. CD003556.
59. Winter GD, (1962) Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature 193: 293-294.
60. Hinman CD, Maibach H, (1963) Effect of Air Exposure and Occlusion on Experimental Human Skin Wounds. Nature 200: 377-378.
61. Barker AT, Jaffe LF, Vanable JW Jr, (1982) The glabrous epidermis of cavies contains a powerful battery. Am J Physiol 242: R358-366.
62. Zhao M, Song B, Pu J, Wada T, Reid B, et al. (2006) Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature 442: 457-460.
63. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V, (1991) Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol 25: 1054-1058.
64. Werner S, Grose R, (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83: 835-870.
65. Safi N, Davis GD, Nadir M, Hamid H, Robert LL Jr, et al. (2012) Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial. Mil Med 177: 345-351.
66. Zenker W, Thiede A, Dommes M, Ullmann U, (1986) [Effectiveness of tetrachlorodecaoxide (TCDO) in the treatment of complicated disorders of wound healing. A controlled study: TCDO versus PVP-iodine complex]. Chirurg 57: 334-339.
67. Wolin MS, Kleber E, Mohazzab KM, Elstner EF, (1994) Tetrachlorodecaoxygen, a wound healing agent, produces vascular relaxation through hemoglobulin-dependent inactivation of serotonin and norepinephrine. J Cardiovasc Pharmacol 23: 664-668.
68. Boecken G, Sunderkotter C, Bogdan C, Weitzel T, Fischer M, et al. (2011) Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany. J Dtsch Dermatol Ges 9 Suppl 8: 1-51.
69. Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A, (2012) Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol 51: 1221-1225.
70. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, et al. (2006) Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 3: e162.
71. den Boer M, Argaw D, Jannin J, Alvar J, (2011) Leishmaniasis impact and treatment access. Clin Microbiol Infect 17: 1471-1477.
72. Khamesipour A, Seby F (2013) High levels of arsenic and lead in a meglumine antimoniate product used in a middle eastern country. Fifth World Congress on Leishmaniasis, Porto de Galinhas, Pernambuco, Brazil, May 13 to 17, 2013, Abstract 1284.
73. Rodriguez ME, Inguanzo P, Ramos A, Perez J, (1990) [Treatment of cutaneous leishmaniasis with CO2 laser radiation]. Rev Cubana Med Trop 42: 197-202.
74. Babajev KB, Babajev OG, Korepanov VI, (1991) Treatment of cutaneous leishmaniasis using a carbon dioxide laser. Bull World Health Organ 69: 103-106.
75. Asilian A, Sharif A, Faghihi G, Enshaeieh S, Shariati F, et al. (2004) Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis. Int J Dermatol 43: 736-738.
76. Shamsi Meymandi S, Zandi S, Aghaie H, Heshmatkhah A, (2011) Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J Eur Acad Dermatol Venereol 25: 587-591.
77. Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, et al. (2013) Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. PLoS One 8: e66123.
78. Navarro M, Cisneros-Fajardo EJ, Marchan E, (2006) New silver polypyridyl complexes: synthesis, characterization and biological activity on Leishmania mexicana. Arzneimittelforschung 56: 600-604.
79. Allahverdiyev AM, Abamor ES, Bagirova M, Rafailovich M, (2011) Antimicrobial effects of TiO(2) and Ag(2)O nanoparticles against drug-resistant bacteria and leishmania parasites. Future Microbiol 6: 933-940.
80. Aziz Z, Abu SF, Chong NJ, (2012) A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds. Burns 38: 307-318.
81. Morizot G, Kendjo E, Mouri O, Thellier M, Perignon A, et al. (2013) Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis 57: 370-380.
82. Killingley B, Lamb LE, Davidson RN, (2009) Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol 103: 171-175.
83. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, et al. (2011) Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 25: 973-977.
84. Plourde M, Coelho A, Keynan Y, Larios OE, Ndao M, et al. (2012) Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan. PLoS Negl Trop Dis 6: e1463.
85. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L, (1986) Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 87: 284-288.
86. Kim DH, Chung HJ, Bleys J, Ghohestani RF, (2009) Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 3: e381.
87. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, et al. (2013) Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524-532.
88. Pocock SJ, Assmann SE, Enos LE, Kasten LE, (2002) Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 21: 2917-2930.